RNASET2 and cancer: The in vivo oncosuppressive activity of RNASET2 involves the establishment of a crosstalk between RNASET2-expressing cancer cells and components of the tumor microenvironment (TME) belonging to the innate immune system (mostly tissue macrophages) [7].